Literature DB >> 19637984

Delivery of antibiotics to the respiratory tract: an update.

Daniela Traini1, Paul M Young.   

Abstract

The use of inhaled medications for the treatment of pulmonary diseases has become an increasingly popular drug delivery route over the past few decades. This delivery route allows for a drug to be delivered directly to the site of the disease, with a lower dose than more conventional oral or intravenous delivery methods, with reduced systemic absorption and consequently reduced risk of adverse effects. For asthma this delivery route has become the 'golden standard' of therapy. It is not unexpected therefore, that there has been great interest in the prospect of using inhaled antibiotics for the treatment of both chronic and recurrent respiratory infections. Since the early 1980s, several investigations have demonstrated that antibiotics could be delivered safely by means of inhalation, using nebulisers as their delivery systems. Lately, antibiotics delivery via inhalation have seen a 'revival' in interest and most of these studies have focused on delivering antibiotics to the lungs by means of a dry powder format. This review focuses on recent advances in antibiotic inhalation therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19637984     DOI: 10.1517/17425240903110710

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  12 in total

1.  Antibacterial efficacy of inhalable levofloxacin-loaded polymeric nanoparticles against E. coli biofilm cells: the effect of antibiotic release profile.

Authors:  Wean Sin Cheow; Matthew Wook Chang; Kunn Hadinoto
Journal:  Pharm Res       Date:  2010-04-21       Impact factor: 4.200

2.  Synergistic antibiotic combination powders of colistin and rifampicin provide high aerosolization efficiency and moisture protection.

Authors:  Qi Tony Zhou; Thomas Gengenbach; John A Denman; Heidi H Yu; Jian Li; Hak Kim Chan
Journal:  AAPS J       Date:  2013-10-16       Impact factor: 4.009

3.  Understanding the Impacts of Surface Compositions on the In-Vitro Dissolution and Aerosolization of Co-Spray-Dried Composite Powder Formulations for Inhalation.

Authors:  Sharad Mangal; Rongkun Xu; Heejun Park; Dmitry Zemlyanov; Nivedita Shetty; Yu-Wei Lin; David Morton; Hak-Kim Chan; Jian Li; Qi Tony Zhou
Journal:  Pharm Res       Date:  2018-11-07       Impact factor: 4.200

4.  Solid lipid budesonide microparticles for controlled release inhalation therapy.

Authors:  Matteo Mezzena; Santo Scalia; Paul M Young; Daniela Traini
Journal:  AAPS J       Date:  2009-11-12       Impact factor: 4.009

5.  Epithelial profiling of antibiotic controlled release respiratory formulations.

Authors:  Hui Xin Ong; Daniela Traini; Mary Bebawy; Paul Michael Young
Journal:  Pharm Res       Date:  2011-05-26       Impact factor: 4.200

6.  Improved Aerosolization Stability of Inhalable Tobramycin Powder Formulation by Co-Spray Drying with Colistin.

Authors:  Vaibhav Pathak; Heejun Park; Dmitry Zemlyanov; Sonal V Bhujbal; Maizbha Uddin Ahmed; Mohammad A K Azad; Jian Li; Qi Tony Zhou
Journal:  Pharm Res       Date:  2022-08-02       Impact factor: 4.580

7.  Composite particle formulations of colistin and meropenem with improved in-vitro bacterial killing and aerosolization for inhalation.

Authors:  Sharad Mangal; Heejun Park; Lingfei Zeng; Heidi H Yu; Yu-Wei Lin; Tony Velkov; John A Denman; Dmitry Zemlyanov; Jian Li; Qi Tony Zhou
Journal:  Int J Pharm       Date:  2018-07-03       Impact factor: 5.875

8.  How Much Surface Coating of Hydrophobic Azithromycin Is Sufficient to Prevent Moisture-Induced Decrease in Aerosolisation of Hygroscopic Amorphous Colistin Powder?

Authors:  Qi Tony Zhou; Zhi Hui Loh; Jiaqi Yu; Si-Ping Sun; Thomas Gengenbach; John A Denman; Jian Li; Hak-Kim Chan
Journal:  AAPS J       Date:  2016-06-02       Impact factor: 4.009

9.  Study of nebulization delivery of aerosolized fluorescent microspheres to the avian respiratory tract.

Authors:  Lisa A Tell; Kimberly Stephens; Stephen V Teague; Kent E Pinkerton; Otto G Raabe
Journal:  Avian Dis       Date:  2012-06       Impact factor: 1.577

Review 10.  New opportunities for managing acute and chronic lung infections.

Authors:  William O C M Cookson; Michael J Cox; Miriam F Moffatt
Journal:  Nat Rev Microbiol       Date:  2017-10-24       Impact factor: 60.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.